Old Age; Debility, Sarcopenia, Sensitivity
Conditions
Brief summary
The study applies the Sluggishness, Assistance in walking, Rising from a chair, Climb stairs, Falls (SARC-F) questionnaire in older patients hospitalized in an acute care geriatric unit and aims to determine its performance indicators to screen for sarcopenia according to the revised European Consensus on definition and diagnosis (EWGSOP2) within this population
Detailed description
Sarcopenia is an age-related disease associated with health adverse outcomes, i.e. higher risk of mobility limitation, falls, fractures, mortality, and lower quality of life. The European Working Group on Sarcopenia has recently revisited one of the widely used most acknowledged definitions and launched the revised European consensus on definition and diagnosis (EWGSOP2) (4). Applying the EWGSOP2 is a three-tier process: first, screening by the Sluggishness, Assistance in walking, Rising from a chair, Climb stairs, Falls (SARC-F) questionnaire; second, diagnosis by low muscle strength, and low muscle mass; third, severity grading by low muscle function. The EWGSOP2 recommends the assessment of sarcopenia in every population, both in community-dwelling and acute care older patients. However, the evidence about the performance indicators of the SARC-F questionnaire to screen for sarcopenia in acute patients admitted to an acute care unit is really limited.
Interventions
DIAGNOSTIC_TEST5-item SARC-F questionnaire
Administration of the 5-item SARC-F questionnaire in patients admitted to an acute care unit
Sponsors
Brugmann University Hospital
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients aged 65 and over * Hospitalized in an acute care geriatric unit due to acute health issues or acute medical conditions * With SARC-F, hand-grip strength and dual-energy X-ray absorptiometry administered during hospital admission
Exclusion criteria
* SARC-F unavailable * Unwilling to collaborate in the sarcopenia assessment * Unwilling to sign the informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sensitivity of the SARC-F questionnaire as screening method compared to the gold standard, which is the revised European consensus on definition and diagnosis | September 2019-November 2020 | Sensitivity, measured as a percentage (%) |
| Specificity of the SARC-F questionnaire as a screening method, compared to the gold standard which is the revised European Consensus on definition and diagnosis of sarcopenia (EWGSOP2) | September 2019-November 2020 | Specificity, measured as a percentage (%) |
| Overall concordance agreement between the SARC-F questionnaire as a screening method and the gold standard method, which is the EWGSOP2 | September 2019-November 2020 | Cohen-kappa coefficient, measured as a percentage (%) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Health adverse outcomes based on the screening and diagnosis of sarcopenia as recommended by the EWGSOP2 | 1-year follow-up | Mortality risk |
Countries
Belgium
Outcome results
None listed